Hypomagnesaemia in Diabetes

Authors

Bilal Mohammed¹, Feroz P Jenner², Harris P³, Jesha MM *⁴

¹MD Resident, Department of General Medicine, MES Medical College, Perinthalmanna, Kerala
Email: dr.bilalmohamed@gmail.com; +91-9447777249

²Clinical Professor, Department of General Medicine, MES Medical College, Perinthalmanna, Kerala
Email: drjenner@hotmail.com; +91-944666099

³Clinical Assistant Professor, Dept of General Medicine, MES Medical College, Perinthalmanna, Kerala
Email: drharrispool@gmail.com; +91-9447123300

⁴*Assistant Professor, Department of Community Medicine, MES Medical College, Perinthalmanna, Kerala
Corresponding Author
Jesha MM
Assistant Professor, Department of Community Medicine
MES Medical College, Perinthalmanna, Kerala
Email: jesha_ali@yahoo.com; +91-9446313099

ABSTRACT

Background: Relationship between Diabetes Mellitus and minerals has been reported frequently. Recent studies have demonstrated reduced levels of serum magnesium in diabetes mellitus especially in poorly controlled patients. Clinically, there are significant data linking hypomagnesemia to various diabetic micro- and macrovascular complications. Therefore, Mg supplementation may provide a new therapeutic approach to reducing vascular disease in patients with diabetes.

Objective: To study the levels of serum magnesium in diabetic patients in a tertiary hospital in North Kerala.

Methodology: A hospital based cross sectional study was done in all diabetic patients attending the out-patient and in-patient facilities of Department of Internal Medicine at a tertiary hospital in North Kerala between January 1st and March 31st 2014. Results: In the study hypomagnesaemia was seen in 15.7% of the participants. No significant difference was found in Serum Magnesium neither between genders (p 0.35) nor age (p 0.057). Serum magnesium levels was not seen to have any significant association with duration of diabetes or type of treatment. Significant relation could not be established with other complications associated with type 2 Diabetes Mellitus like hypertension and dyslipidemia. A significant negative correlation was seen between serum magnesium and Fasting blood sugar (p<0.001) as well as HbA1c values (p<0.001). In the present study it was observed that there was significant difference in the level of serum magnesium among controlled and uncontrolled diabetics (p 0.002).

Conclusion: Hypomagnesaemia is common in diabetes and negatively correlated with fasting blood sugar but not related to duration or type of treatment taken.

Keywords: Hypomagnesaemia, Diabetes Mellitus.
INTRODUCTION
Relationship between Diabetes Mellitus and minerals has been reported frequently. Decreased levels of Zn and Mg are associated with increased values of HbA1c. These findings suggest that impaired metabolism of trace elements are involved in pathogenesis of diabetes by participation in oxidative stress. Recent studies have demonstrated reduced levels of serum magnesium in diabetes mellitus especially in poorly controlled patients. This reduction in magnesium level has been attributed to renal losses, decreased intestinal absorption and redistribution of Magnesium from plasma into blood cells caused by insulin effect. Hypermagnesuria results specifically from a reduction in tubular absorption of magnesium. Use of diuretics among patients with diabetes may also contribute to magnesiuria. Finally, the common use of antibiotics and antifungals such as aminoglycosides and amphotericin in patients with diabetes may also contribute to renal Mg wasting. Although many authors have suggested that diabetes per se may induce hypomagnesemia, others have reported that higher Mg intake may confer a lower risk for type 2 diabetes. Hypomagnesemia, has been reported to occur in 13.5 to 47.7% of non-hospitalized patients with type 2 diabetes compared with 2.5 to 15% among their counterparts without diabetes. The wide range in the reported incidence of hypomagnesemia most likely reflects the difference in the definition of hypomagnesemia, techniques in Mg measurements and the heterogeneity of the selected patient cohort. Type 2 diabetes is on track to become one of the major global health challenges of the 21st century. Primary prevention remains the major strategic approach. Clinically, there are significant data linking hypomagnesemia to various diabetic micro- and macrovascular complications. Hypomagnesemia has been demonstrated in patients with diabetic retinopathy, with lower magnesium levels predicting a greater risk of severe diabetic retinopathy. Magnesium depletion has been associated with multiple cardiovascular implications like arrhythmogenesis, vasospasm and hypertension and platelet activity. Magnesium deficiency may have some effects on the development of diabetic vascular complications with other risk factors like systemic hypertension and dyslipidemia. As per some studies, changes in Magnesium levels can affect Insulin action which is mainly attributed to the changes in decreased activity of insulin tyrosine kinase. Long term hyperglycemia in patients with type 2 diabetes increases the risk of chronic complications such as nephropathy, which may exacerbate hypomagnesemia and aggravate the complications. Serum Mg concentration between 2.0 and 2.5 mg/dl in patients with diabetes, may be favorable. Although the correction of low serum Mg levels has never been proved to be protective against chronic diabetic complications, intervention is justified because hypomagnesemia has been linked to many adverse clinical outcomes. Therefore, Mg supplementation may provide a new therapeutic approach to reducing vascular disease in patients with diabetes. In addition, Mg supplementation is inexpensive and, with the exception of diarrhea, a relatively benign medication. Nonetheless, close observation must be given to those with renal insufficiency. The present study is to evaluate serum magnesium levels in Diabetic patients in a tertiary hospital in North Kerala. The present study has particular relevance in Kerala since no study has been reported to determine the prevalence of hypomagnesemia among diabetics.

METHODOLOGY
A hospital based cross sectional study was done in all Diabetes Mellitus patients attending the out-patient and in-patient facilities of Department of Internal Medicine at a tertiary hospital in North Kerala between January1st and March 31st 2014. Inclusion Criteria: Already diagnosed diabetics on treatment even if at the time of inclusion they do not meet the glycaemic criteria for diagnosis;
Symptoms of Diabetes Mellitus plus a Random Blood glucose concentration ≥200mg/dL; Fasting blood glucose ≥126mg/dl and or 2 hour Post Prandial glucose ≥200mg/dL.

**Exclusion Criteria:** Patients on Diuretic/amphotericin/ Protein Pump Inhibitors therapy/ Iatrogenic magnesium administration

Data was collected using a pre-tested structured questionnaire and clinical examination findings were recorded. Relevant investigations including fasting blood sugar, glycated hemoglobin and serum magnesium were done. Hypomagnesemia was defined as a serum Mg concentration <1.6 mg/dl. Glycated hemoglobin values 6-7 means good control, between 7-8 means diabetes under moderate control and values more than 8 indicates poor control. Descriptive analysis was done.

**RESULTS**

A total of 70 diabetic patients were studied during the study period. Half (51.4%) of the subjects were males. Table 1 shows the baseline characteristics of these 70 subjects.

The age of the study population ranged between 36 and 95 with a mean age of 55.93 years (±10.03). Three fourths (75%) are aged between 50 – 69 years. Very few (4.3%) had gone beyond high school education. Most (98.6%) were currently married and one person was widowed. Half of the diabetic subjects (54.3%) reported having used some type of tobacco products and 10% reported alcohol consumption. Twenty three (32.9%) subjects gave history of diabetes in their families. The duration of diabetes was found to be between 1 and 30 years with a mean duration of 9.71 years (± 6.125). Thirty one subjects (44%) were diabetic for the past 10 years and another 35 (50%) for the past 10 – 20 years. Only 3 were diabetic for more than 20 years. No relation was seen between duration of diabetes and Serum Magnesium (p 0.736).

Except for 2 on dietary control alone, the remaining 68 were on some kind of medications. Table 2 depicts the treatment pattern followed by these subjects. Nearly three-fourths (72.86%) were on oral hypoglycemic agents and a few (17.14%) were on both OHA and Insulin. No significant difference was seen in serum magnesium between the treatment modality the patient is taking (p 0.855). Table 3 shows the proportion of subjects having other co-morbidities. A quarter (24.28%) had hypertension and 8.5% had history of coronary artery disease and peripheral vascular disease each.

Table 4 depicts the distribution of the study participants based on of Fasting blood sugar values, Serum magnesium levels and control based on HbA1c level. The table also gives the mean (± SD) of these variables. Most (82.9%) of the subjects had a fasting blood sugar value >126mg/dL. The blood sugar levels of majority (62.9%) were found to be under poor control based on HbA1c level. Hypomagnesemia (<1.6 mg/l) was found in 15.7% (10) subjects.

The mean FBS level was found to be higher in the hypomagnesemic group when compared to the normomagnesemic group as shown in Table 5. This difference was found to be significant (p 0.003). A negative correlation was found between serum Magnesium and Fasting Blood Sugar (r - 0.349; p 0.003) ie as FBS value increases the S.Magnesium will decrease.

Similarly, the mean HbA1c value was higher in hypomagnesemic patients when compared to partients with normal magnesium levels (Table 5). The finding that patients with hypomagnesemia have poorly controlled diabetes has been found to be significant (p 0.002). A negative correlation was found between HbA1c and serum Magnesium (-0.296; p 0.013) ie as HbA1c increases the S.Magnesium will decrease.

No significant significant difference was found in Serum Magnesium levels between males (mean S.Mg 1.89 + 0.35) and females (mean S.Mg 1.82 + 0.281) [ t 0.941; p 0.35].
### Table 1: Baseline characteristics of study subjects

| Baseline characteristics | Number | Percentage |
|--------------------------|--------|------------|
| AGE                      |        |            |
| 30-39 years              | 5      | 7.1        |
| 40 – 49 years            | 9      | 12.9       |
| 50 – 59 years            | 33     | 47.1       |
| 60 -69 years             | 20     | 28.6       |
| ≥70 years                | 3      | 4.3        |
| EDUCATIONAL QUALIFICATIONS |      |            |
| Illiterate               | 5      | 7.1        |
| Lower primary            | 9      | 12.9       |
| Upper primary            | 33     | 47.1       |
| High school              | 20     | 28.6       |
| Graduation               | 3      | 4.3        |
| OCCUPATIONAL STATUS      |        |            |
| Unemployed               | 5      | 7.1        |
| Unskilled                | 35     | 50         |
| Semiskilled              | 19     | 27.1       |
| Skilled                  | 8      | 11.4       |
| Professional             | 3      | 4.3        |
| TOTAL                    | 70     | 100        |

### Table 2: Treatment pattern of the diabetic patients

| Treatment pattern                  | Number | Percentage |
|------------------------------------|--------|------------|
| OHA                                 | 51     | 72.86%     |
| Insulin                            | 5      | 7.14%      |
| both Insulin and OHA               | 12     | 17.14%     |
| dietary restriction                | 2      | 2.85%      |

### Table 3: Co-morbidity profile

| Comorbidity                  | Number | Percentage |
|------------------------------|--------|------------|
| Hypertension                 | 17     | 24.28%     |
| Renal Disease                | 2      | 2.86%      |
| Peripheral Vascular D/S      | 6      | 8.57%      |
| Cva                          | 3      | 4.28%      |
| Coronary Artery D/S          | 6      | 8.57%      |
| Thyroid D/S                  | 2      | 2.86%      |

### Table 4: Laboratory parameters

| Variable                  | Number (%) | Mean (± SD) | Min.value | Max.value |
|---------------------------|------------|-------------|-----------|-----------|
| Serum magnesium           |            |             |           |           |
| <1.6 mg/l                 | 11 (15.7)  | 1.86 (+ 0.32) | 1         | 3         |
| 1.6 – 2.3 mg/l            | 53 (75.7)  |             |           |           |
| >2.3 mg/l                 | 6 (8.6)    |             |           |           |
| Fasting Blood Sugar       |            |             |           |           |
| 80-110 (normal)           | 3 (4.3)    | 169.37 (+48.77) | 100     | 295      |
| 111-126 (impaired)        | 9 (12.9)   |             |           |           |
| >126 (hyperglycemic)      | 58 (82.8)  |             |           |           |
| HbA1c                     |            |             |           |           |
| 5.1-6 (normal)            | 2 (2.9)    | 8.74 (+ 1.59) | 5         | 13       |
| 6-7 (good control)        | 6 (8.6)    |             |           |           |
| 7-8 ( moderate control)   | 17 (24.3)  |             |           |           |
| >8 (poor control)         | 44 (62.9)  |             |           |           |

### Table 5: Fasting blood sugar/ HbA1c and status of serum magnesium

| Serum magnesium status | Variable | Frequency | Mean   | SD    | *t*   | Significance |
|------------------------|----------|-----------|--------|-------|-------|--------------|
| Hypomagnesemia         | FBS      | 10        | 211.00 | 60.72 | 3.091 | 0.003        |
| Normomagnesemia        |          | 60        | 162.43 | 43.32 |       |              |
| Hypomagnesemia         | HbA1c    | 10        | 10.14  | 1.88  | 3.191 | 0.002        |
| Normomagnesemia        |          | 60        | 8.51   | 1.43  |       |              |
DISCUSSION
Hypomagnesemia is a common feature in patients with Type 2 Diabetes Mellitus. This study was designed to find out the serum magnesium levels and its influence on Type 2 diabetics and how it is associated with duration, treatment modalities and complication of the disease. The present study included 70 Diabetes Mellitus patients.

In this study hypomagnesemia was seen in 15.7% of the participants an this falls within the range seen in another study (13.5- 47.7%) among non-hospitalized patients with type 2 diabetes. The study conducted by AP Jain et al in 1986 had 32% diabetic subjects below 1.6mg/dl.

In the present study no significant difference was found in Serum Magnesium between males and females (p 0.35). In the present study no significant association with duration of diabetes and serum magnesium levels. There was no significant difference noted when analyzed serum magnesium levels between OAD and insulin treated patients with which was against the observation obtained by previous studies by Yajnik CS et al and AP Jain et al. In the present study it was observed that there was significant difference in the level of serum magnesium among controlled and uncontrolled diabetics (p0.002).Observation made in recent studies by Sharma A et al, Mishra S et al and Nasri H et al proved the same. Earlier studies done by Nagase N et al also had similar findings. Numerous studies have reported an inverse relationship between glycemic control and serum Mg levels similar to our findings in this study (-0.296; p 0.013).

Other associated complications of type 2 Diabetes Mellitus like hypertension and dyslipidemia was also analyzed with serum magnesium but could not establish significant relation. In our study a significant negative correlation existed as for Fasting blood sugar and HbA1c with serum magnesium (p<0.001). As the plasma fasting glucose levels and HbA1c increases the serum magnesium levels dropped. Sharma A et al, Mishra S et al and few other recent studies also established the same i.e. there is a negative correlation between fasting blood sugars and HbA1c with plasma magnesium.

In the present study no significant association with duration of diabetes and serum magnesium levels was observed which was statistically analyzed with ANOVA. It was noticed that as the duration of diabetes increases the serum magnesium values showed a low normal values. Sharma A et al, Mishra S et al, Walti MK et al also had similar observations and came to a conclusion of an inverse correlation of duration of diabetes and serum magnesium.

CONCLUSION
In this study hypomagnesemia was seen in 15.7% of the participants. No significant difference was found in Serum Magnesium between the genders (p 0.35) nor between age of the cases and serum magnesium levels (p=0.057). In the present study no significant association with duration of diabetes and serum magnesium levels. There was no significant difference noted when analyzed serum magnesium levels between OAD and insulin treated patients. Other associated complications of type 2 Diabetes Mellitus like hypertension and dyslipidemia was also analyzed with serum magnesium but could not establish significant relation.

In our study a significant negative correlation existed as for Fasting blood sugar and HbA1c
values with serum magnesium (p<0.001). In the present study it was observed that there was significant difference in the level of serum magnesium among controlled and uncontrolled diabetics (p<0.002).

**LIMITATIONS OF THE STUDY**

Plasma magnesium is relatively an insensitive measurement of magnesium status of the body because major bulk of magnesium lies within the cell. Intra erythrocyte magnesium and urinary magnesium are not done in the present study due to lack of facility and financial burden. There is no follow up in this study hence change in magnesium states with respect to improvement or worsening of diabetic state in the long run is not studied. This study focuses on magnesium levels in type 2 Diabetes mellitus at a given point but not on therapeutically correcting hypomagnesemia or otherwise not correcting in the future course of the disease and its outcome.

**REFERENCES**

1. Aguilar MV, Saavedra P, Arrieta FJ, Mateos CJ, Gonzalez MJ, Meseguer I, Martinez – Para MC. Plasma mineral content in type-2 diabetic patients and their association with the metabolic syndrome. Ann Nutr Metab. 2007;51(5): 402-6.

2. White JR, Campbell RK: Magnesium and diabetes: A review. *Ann Pharmacother* 27: 775–780, 1993

3. Altered metabolism of copper, zinc, and magnesium is associated with increased levels of glycated hemoglobin in patients with diabetes mellitus. Viktorínová A, Toserová E, Krizko M, Duracková Z. Metabolism. 2009 Oct;58(10): 1477–82.

4. Guerrero Romero F, Rodriguez Moran M. Hypomagnesemia: oxidative stress, inflammation, and metabolic syndrome. Diabetic Metabolic Res Rev. 2006. Nov-Dec. 22(6); 471-6

5. Sharma A, Dabla S, Agrawal RP, Barjatya H, Kochar DK, Kothari RP. Serum magnesium: an early predictor of course and complications of diabetes mellitus. *J Indian Med Assoc*. 2007 Jan;105(1): 16-20

6. Pham PC, Pham PM, Pham PA, Pham SV, Pham HV, Miller JM, Yanagawa N, Pham PT: Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. *Clin Nephrol* 63: 429–436, 2005

7. Hodler J, Roulin F, Haldimann B: Short-term effect of thiazides on magnesium and calcium metabolism and secondarily on that of phosphorus, uric acid, oxalate and cyclic AMP [in French]. *Nephrologie* 4: 60–63, 1983

8. Tong GM, Rude RK: Magnesium deficiency in critical illness. *J Intensive Care Med* 20: 3–17, 2005

9. Kao WH, Folsom AR, Nieto J, Mo JP, Watson RL, Brancati FL: Serum and dietary magnesium and the risk for type 2 diabetes mellitus. The Atherosclerosis Risk in Communities study. *Arch Intern Med* 159: 2151–2159, 1999

10. Lopez-Ridaura R, Willett WC, Rimm EB, Liu S, Stampfer MJ, Manson JE, Hu FB: Magnesium intake and risk of type 2 diabetes in men and women. *Diabetes Care* 27: 134–140, 2004

11. Song Y, Manson JE, Buring JE, Liu S: Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. *Diabetes Care* 27: 59–65, 2004

12. McNair P, Christensen MS, Christiansen C, Madsbad S, Transbol I: Renal hypomagnesaemia in human diabetes mellitus: Its relation to glucose homeostasis. *Eur J Clin Invest* 12: 81–85, 1982

13. Tosiello L: Hypomagnesemia and diabetes mellitus. *Arch Intern Med* 156: 1143–1148, 1996
14. Mather H, Nisbet JA, Burton GH, Poston GJ, Bland JM, Bailey PA, Pilkington TR: Hypomagnesemia in diabetes. *Clin Chim Acta* 95: 235–242, 1979
15. Paolisso G, Sgambato S, Gambardella A, Pizza G, Tesauro P, Varricchio M, D’Onofrio F: Daily magnesium supplements improve glucose handling in elderly subjects. *Am J Clin Nutr* 55: 1161–1167, 1992
16. Elamin A, Tuvemo T: Magnesium and insulin-dependent diabetes mellitus. *Diabetes Res Clin Pract* 10: 203–209, 2006
17. Nadler J, Buchanan T, Natarajan R, Antoipillai I, Bergman R, Rude R: Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. *Hypertension* 21: 1024–1029, 1993
18. Jain AP, Gupta NN, Kumar A. Some metabolic facets of magnesium in diabetes mellitus. *J Asso phys Ind* 1976; 24:827-830.
19. De Lordes Lima M, Cruz T, Pousada JC, Rodrigues LE, Barbosa K, Cangucu V: The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care* 21: 682–686, 1998
20. Walti MK, Zimmermann MB, Spinas GA, Hurrell RF: Low plasma magnesium in type 2 diabetes. *Swiss Med Wkly* 133: 289–292, 2003
21. Sheehan JP: Magnesium deficiency and diabetes mellitus. *Magnes Trace Element* 10: 215–219, 1991–1992
22. Mikhail N, Ehsanipoor K: Ionized serum magnesium in type 2 diabetes mellitus: Its correlation with serum magnesium and hemoglobin A1C levels. *South Med J* 92: 1162–1166, 1999
23. Mishra S, P Padmanaban, GN Deepti, GSarkar, S Sumathi, BD Toora: Serum Magnesium and Dyslipidemia in Type-2 Diabetes Mellitus. *Biomedical Research* 2012; 23 (2): 295-300.
24. Nasri H, Hamid-Reza Baradaran: Lipids in association with serum magnesium in diabetes mellitus patients. *Bratisl Lek Listy* 2008; 109(7): 302-306
25. Yajnik CS, Smith RF, Hockaday TD, Ward NI. Fasting plasma magnesium concentrations and glucose disposal in diabetes. *BMJ* 1984; 288:1032-1034.
26. Nagase N. Hypertension and serum magnesium in the patients with diabetes and coronary heart disease. *Hypertens Res* 1996;19:65-68.
27. Sjogren AS, Floren CH, Nilsson A: Magnesium deficiency in IDDM related to level of glycosylated hemoglobin. *Diabetes* 35: 459–463, 1986
28. Pon KK, Ho PWM: Subclinical hyponatremia, hyperkalemia and hypomagnesemia in patients with poorly controlled diabetes mellitus. *Diabetes Res Clin Pract* 7: 163–167, 1989
29. Resnick L, Altura BT, Gupta RK, Laragh JH, Alderman MH, Altura BM: Intracellular and extracellular magnesium depletion in type 2 (non-insulin-independent) diabetes mellitus. *Diabetologia* 36: 767–770, 1993.